A5018744683- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Economic and Financial Impacts of Cancer
- Acute Myeloid Leukemia Research
- Renal Transplantation Outcomes and Treatments
- Healthcare Policy and Management
- Biomedical Ethics and Regulation
- Health Systems, Economic Evaluations, Quality of Life
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Primary Care and Health Outcomes
- Childhood Cancer Survivors' Quality of Life
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Prenatal Screening and Diagnostics
- Oral and gingival health research
- Oral and Maxillofacial Pathology
- Science, Research, and Medicine
- CRISPR and Genetic Engineering
- Pluripotent Stem Cells Research
- Chronic Lymphocytic Leukemia Research
- Oral Health Pathology and Treatment
- Neutropenia and Cancer Infections
- Adolescent and Pediatric Healthcare
- Biotechnology and Related Fields
- Hemoglobinopathies and Related Disorders
Blue Cross Blue Shield Association
2020
National Marrow Donor Program
2013-2019
American Society for Transplantation and Cellular Therapy
2017
Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed in the United States annually. With advances technology and supportive care practices, HCT has become safer, patient survival continues to improve over time. Indications for continue evolve as research refines role established indications identifies emerging where may be beneficial. The American Society Blood Marrow Transplantation (ASBMT) a multiple-stakeholder task force consisting of transplant experts,...
<h3>Importance</h3> In 2010, the US Centers for Medicare & Medicaid Services (CMS) indicated that data regarding efficacy of allogeneic hematopoietic stem cell transplantation (HCT) in CMS beneficiary population with myelodysplastic syndrome (MDS) were currently insufficient, but coverage would be provided patients enrolled a clinical study met its criteria Coverage Evidence Development (CED). <h3>Objective</h3> The Center International Bone Marrow Transplant Research (CIBMTR) submitted...
The primary aim of this study was to describe healthcare costs and utilization during the first year after a diagnosis acute myeloid leukemia (AML) for privately insured non-Medicare patients in United States aged 50 64 years who were treated with either chemotherapy or allogeneic hematopoietic cell transplantation (alloHCT). MarketScan (Truven Health Analytics) adjudicated total payments inpatient, outpatient, prescription drug claims from 2007 2011 used estimate health system perspective....
The nomenclature describing hematopoietic stem cell transplantation has evolved, adding precision and definition in research regulation. lack of coordination standardization terminology left some gaps the episodes clinical care. These voids have caused particular problems contracting for payment billing services rendered. purpose this report is to propose definitions products, infusions, episodes.
Findings highlight substantial variation in Medicaid coverage for HCT by state, which may increase disparities access already medically underserved populations.
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia non-Hodgkin's lymphoma is setting the stage what possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, costs associated CAR therapy. To begin to address these issues, NCCN...
Hematopoietic cell transplantation (HCT) is an expensive, medically complicated, and potentially life-threatening therapy for multiple hematologic nonhematologic disorders with a prolonged trajectory of recovery. Similar to financial issues in other cancer treatments, adverse consequences HCT are emerging as important issue may be associated poor quality life increased distress survivors. Prescription medicine coverage Medicare some Medicaid beneficiaries, especially the long-term, remains...
Variability in transplantation benefits may directly affect outcomes of individuals undergoing autologous or allogeneic hematopoietic stem cell procedures. The Financial Working Group the National Marrow Donor Program–sponsored System Capacity Initiative addressed issue variable and reviewed multiple benefit packages from both public private payer organizations. On completion review, a consensus was obtained on defining recipient package that avoids major coverage gaps could negatively...
Patient-centered medical home models are fundamental to the advanced alternative payment defined in Medicare Access and Children's Health Insurance Plan Reauthorization Act (MACRA). The patient-centered is a model of healthcare delivery supported by mechanisms designed promote coordinated care that simultaneously patient-centric population-oriented. This transformative requires shifting reimbursement include per-patient intended cover services not previously reimbursed such as disease...
Medicaid is a jointly funded federal-state program that provides payment for health services pregnant women, children, parents, seniors and disabled individuals. States establish administer their own programs determine the type, amount, scope of within federal guidelines which mandate coverage certain benefits. Optional benefits can be provided by state lead to wide variation offered. Hematopoietic cell transplant (HCT) not mandatory covered service adults, each has discretion choose whether...
As the field of cellular and genetic therapies transitions from a scientific concept to clinical reality, it has become evident that there are several conflicting or imprecise nomenclatures describe these novel therapeutic products. The lack uniformity accuracy in terminology often creates regulatory, educational, administrative, billing quagmires. Standardization nomenclature for products is essential creation harmonized regulatory developmental framework, development training paradigms...
The number of hematopoietic cell transplants (HCT) for Medicare beneficiaries has dramatically increased, heightening the need to address coverage and reimbursement. Previous analysis CMS claims data by ASBMT NMDP suggested variability HCT programs (HCTP) in coding billing. Addressing these issues may be critical ensure financial solvency HCTP continued access beneficiaries. Sarah Cannon Blood Cancer Network (SCBCN), consisting 5 FACT accredited HCTP, analyzed submitted SCBCN between 1/1/11...